Skip to main content

Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective



The burden of pneumococcal disease in adults aged 65 years and older in Australia is not well defined. This retrospective cross-sectional study calculated rates for pneumococcal pneumonia using data from the Australian Institute of Health and Welfare and from the Bettering Evaluation and Care of Health program.


Invasive pneumococcal disease (IPD) incidence was calculated using National Notifiable Diseases Surveillance System data. Population estimates and pneumonia mortality data were from the Australian Bureau of Statistics. Medical costs were derived from Australian Refined Diagnosis Related Groups and the literature. Clinical and economic burden of pneumococcal pneumonia hospitalisations and general practitioner (GP) visits were described and compared with IPD.


For adults aged ≥65 years, pneumococcal pneumonia hospitalisation incidence was 274 per 100,000 population in 2011–2012. From 2004 to 2012, a mean of 2235 pneumonia hospitalisation deaths were recorded, corresponding to a case fatality rate of 6.1 %. GP visits accounted for the largest portion of healthcare encounters, with an annual average of 455 pneumococcal pneumonia GP visits per 100,000 population from 2008 to 2013. In 2012, IPD incidence was 19 per 100,000 population. The estimated annual costs of treating pneumococcal pneumonia hospitalisations and GP visits were A$55,722,136 and A$1,604,189, respectively. Estimated costs for IPD were A$1,172,986.


The healthcare and economic burden of pneumococcal disease in adults aged ≥65 years in Australia is substantial, with the incidence of pneumococcal pneumonia hospitalisation nearly 15-fold higher than for IPD. Despite this, it remains less recognised than other infectious diseases such as influenza.


Streptococcus pneumoniae is responsible for significant morbidity and mortality, especially in young children and the elderly [1]. In adults, the risk of contracting pneumococcal disease increases markedly with age [2, 3]. Currently, more than 3.3 million adults in Australia are aged 65 years and older, accounting for 14 % of the total population [4]. High rates of pneumonia occur among this population, which is also at an increased risk for invasive pneumococcal disease (IPD) [5].

As a nationally notifiable disease, IPD data have been collected in Australia since 2001. Consequently, a large quantity of data is available for evaluation of IPD disease burden in adults aged ≥65 years. However, IPD likely represents only a small portion of total pneumococcal disease, with non-invasive pneumococcal pneumonia expected to occur much more frequently.

Complications from pneumonia include long-term functional and cognitive impairment [6], and cardiovascular dysfunction [7, 8]. Approximately 12 to 20 % of patients admitted for pneumococcal pneumonia reported ≥1 associated cardiac event upon admission or during hospitalisation, with associated risk for higher mortality [7, 9]; S. pneumoniae was the most frequently identified pathogen among a cohort of hospitalised patients with pneumonia with cardiac events (41 % of patients) [8].

The aim of this retrospective study is to provide current estimates of the clinical and economic burden associated with pneumococcal pneumonia and IPD in individuals aged ≥65 years in Australia by analysing data available from multiple national databases.


Study design

Data from 4 national databases and previously published studies [5, 10, 11] were used to estimate the burden of pneumococcal disease. For the purposes of this study, pneumococcal disease was limited to pneumonia and IPD. Therefore, the study estimated the burden of hospitalisation for all-cause and pneumococcal pneumonia, the frequency of general practitioner (GP) visits for all-cause and pneumococcal pneumonia, and total IPD. The case fatality rates for all-cause pneumonia hospitalisation were also calculated. The costs associated with treating pneumonia and IPD in hospital and at GP visits were estimated. All persons aged ≥65 years living in Australia who had a recorded hospital or GP visit for pneumonia between 2001 and 2013 were included. Similarly, all patients aged ≥65 years who were diagnosed with IPD in 2012 were included. As this study examined anonymised data in national databases, ethics approval and informed consent were not required.

Data collection and analysis

Data for all-cause pneumonia hospitalisation were obtained from the Australian Institute of Health and Welfare (AIHW) for financial years 2001–2012 using the International Classification of Diseases, 10th Revision, Australian Modification (ICD-10-AM) codes J12–J18. Data for all-cause pneumonia GP visits were provided by the University of Sydney from the Bettering Evaluation and Care of Health (BEACH) program from April 2008 to March 2013 [12]. Data for total IPD were extracted from the National Notifiable Diseases Surveillance System (NNDSS) IPD Public Data Set from 2012.

Incidences were calculated by dividing the number of pneumonia hospitalisations/IPD cases by the Australian population for the corresponding years, according to the Australian Bureau of Statistics (ABS) [13]. The frequency of pneumonia GP visits were calculated by dividing the number of GP visits by the average Australian population for the corresponding years from the ABS population projections [14]. Data from AIHW, BEACH, and NNDSS were stratified into age groups of 65–74 years, 75–84 years, and ≥85 years. The IPD data from the NNDSS were also stratified according to the clinical presentations of pneumonia, bacteraemia, and meningitis.

Calculations of the proportions of pneumococcal pneumonia in Australia were based on the midpoint between the Australian Community-Acquired Pneumonia Study (ACAPS) by Charles et al. (13.9 %) [10] and the systematic review by Said et al. (27.3 %) [5]. This approach was taken because the results in the ACAPS may be an underestimate, as more than half of the cases were recorded as ‘no aetiology’ (54.4 %) and a large proportion of pneumococcal CAP episodes were identified from positive Alere BinaxNOW® Streptococcus pneumoniae urinary antigen test (Alere Binax, United States) data alone (58 of 123). The sensitivity of BinaxNOW (Binax) has been estimated in recent systematic reviews and meta-analyses to be 66–75 % [15, 16]. A study of the diagnostic accuracy of a newly developed serotype-specific antigen test estimated that the addition of this test to conventional diagnostic methods increased the prevalence of S. pneumoniae community-acquired pneumonia by 39 % [17]. Other techniques such as quantitative PCR analysis followed by capsular sequence typing and inhibition multiplex immunoassay have also been identified, indicating that the true proportion of pneumococcal pneumonia may be higher. In one study, pneumococcus was detected in samples from 56 % more patients compared with conventional methods including Binax [18]. In contrast, the results from the systematic review may be an overestimate, as diagnosis of pneumococcal CAP cases was made by sputum culture only, without other microbiological test confirmation or newer diagnostic methods.

Data for all-cause pneumonia deaths were supplied from the ABS. Case fatality rates (CFRs) were calculated by dividing the average number of deaths attributed to ICD-10-AM codes J12–J18 from the 2004 to 2012 financial years by the average number of pneumonia hospitalisations (J12–J18) from the corresponding period.

Data to estimate the costs of treating pneumonia hospitalisations and IPD were derived from the National Hospital Cost Data Collection for public hospitals (Australian Refined Diagnosis Related Groups [AR-DRG]) [19]; private hospitals were excluded, as the cost weights do not include Medicare Benefits Schedule (MBS) costs, and therefore underestimate the total treatment cost. The AR-DRG items selected were E62A, E62B, and E62C for pneumonia hospitalisation; T60A and T60B for bacteraemia; and B72A and B72B for meningitis. Data to estimate the costs of treating pneumonia GP visits were sourced from Li and colleagues [11]. As Australian costs for pneumococcal pneumonia are not available, it was assumed that costs were the same as those associated with the treatment of all-cause pneumonia hospitalisation and GP visits. Primary costs per pneumonia episode for GP visits included ongoing care, specialists, medications, diagnostics, and allied health services (physiotherapy).

All authors had full access to all data in the study.


Pneumonia hospitalisation

Hospitalisation incidence for all-cause pneumonia in adults aged ≥65 years between 2001 and 2012 is shown in Fig. 1. For the financial year 2011–2012, 43,336 pneumonia hospitalisations were reported, corresponding to an incidence rate of 1347 per 100,000 population (Table 1). Incidence rates were higher in subjects ≥85 years of age (3507 per 100,000 population) compared with those 65–74 years old (662 per 100,000). Pneumococcal pneumonia accounted for 20.6 % (13.9–27.3 %) of hospitalisations, with an incidence of 274 per 100,000 population (Table 1).

Fig. 1
figure 1

All-cause pneumonia hospitalisations for financial years 2001–2012. Incidence of all-cause pneumonia hospitalisations are shown per 100,000 population for adults aged 65–74 years, 75–84 years, ≥85 years, and all 3 age groups combined

Table 1 Annual Australian age-specific incidence of pneumococcal disease

Pneumonia GP visits

Between April 2008 and March 2013, the average annual number of GP visits in Australia was reported as 119,300,000 visits. Of these, 78,000 were documented as pneumonia GP visits by adults aged ≥65 years, corresponding to approximately 2525 (95 % CI 2246–2800) visits per 100,000 population (Table 1). The frequency of GP visits for all-cause pneumonia ranged from 1591 per 100,000 in patients aged 65–74 years to 5485 per 100,000 in patients aged ≥85 years.

Because pneumonia GP visits are not specified by pathogen, application of the same proportion of all-cause pneumonia calculated as pneumococcal pneumonia (20.6 %) was used to estimate the frequency of GP visits for pneumococcal pneumonia at 455 per 100,000 for all adults 65 years and older. These values ranged from 287 to 989 per 100,000 in the younger and older age subgroups, respectively (Table 1).

Invasive pneumococcal disease

In 2012, a total of 613 IPD cases were reported in adults aged ≥65 years in Australia, corresponding to an incidence of 19 cases per 100,000 population. Of these cases, 72 % were diagnosed as pneumonia (n = 439), 15 % as bacteraemia (n = 89 cases), 5 % as meningitis (n = 28 cases), and 9 % as other (n = 54 cases). A clinical presentation was not recorded for all cases of IPD (Table 1).

The estimate of invasive pneumonia is likely a significant underestimate as blood cultures are frequently not taken.

Case fatality rates

In 2011, 118,553 deaths due to all causes in adults ≥65 years of age were reported to the AIHW. Between 2004 and 2012, the mean number of pneumonia hospitalisation deaths per year in adults aged ≥65 years attributed to ICD-10-AM codes J12–J18 was 2235.1, which corresponds to a CFR of 6.1 %. The 30-day fatality rate for pneumococcal pneumonia was estimated at 8.1 % based on the number of pneumococcal pneumonia deaths reported by Charles et al. [10] (PGP Charles, personal email communication, March 10, 2015). In this population, the CFR associated with IPD ranged from 14.3 to 16.4 % [20, 21].

Economic burden of pneumonia

The total medical costs associated with public hospitalisation for pneumonia and the IPD clinical presentations of bacteraemia and meningitis were based on data from the Australian National Hospital Cost Data Collection. For AR-DRG items E62A, E62B, and E62C, pneumonia hospitalisation costs were A$6242 per person. For bacteraemia (AR-DRG items T60A and T60B), the average weighted treatment cost was A$10,148. The estimated average cost per pneumonia GP visit was based on the findings of Li and colleagues [11], which examined data collected from April 2006 to March 2009 by BEACH. An estimated A$114 was spent on 2 GP visits per episode of pneumonia. In 2012, the estimated annual cost of treating IPD was A$1,172,986.

Costs associated with all-cause pneumonia hospitalisation were estimated at A$270,495,804; costs associated with pneumococcal pneumonia hospitalisation were estimated at A$55,722,136. Estimated costs for GP visits for all-cause and pneumococcal pneumonia were A$8,899,800 and A$1,604,189, respectively. Taken together, the annual total cost of treating pneumococcal disease in adults aged ≥65 years was A$58,499,310.


The clinical and economic burden of pneumococcal disease in adults aged 65 years and older in Australia is substantial, but has not been well described. IPD data have been collected in Australia since 2001, but relatively few publications have been produced despite robust datasets. Although most data available for pneumococcal disease relate to IPD, pneumococcal pneumonia represents a much larger but previously undescribed disease burden in elderly adults in Australia. We estimated that compared with IPD incidence, the rate of pneumococcal pneumonia hospitalisation and frequency of pneumococcal pneumonia GP visits were nearly 15- and 24-fold higher, respectively (Fig. 2a). These values climb markedly with age, reaching as high as 5780 GP visits per 100,000 population in adults aged 85 and older. To reduce the possibility of overcounting pneumonia GP visits, BEACH calculated that 12.5 % of patients were referred to hospital and/or emergency departments for pneumonia [12]. As a result, GP visit frequency fell slightly to 2209 per 100,000 population, but remained positively correlated with age.

Fig. 2
figure 2

Distribution of pneumococcal disease (a) incidence and (b) associated costs. Estimated incidence per 100,000 population and costs associated with IPD, pneumococcal pneumonia hospitalisation, and pneumococcal pneumonia GP visits. Data for IPD are also shown by clinical presentation (pneumonia, bacteraemia and meningitis). GP, general practitioner; IPD, invasive pneumococcal disease

Considering the frequency of healthcare encounters for pneumonia, the economic burden of treating this disease in adults aged 65 years and older is correspondingly large. Healthcare costs associated with pneumonia are significant: approximately €10–12 billion is spent annually to treat pneumonia patients in Europe [6, 22], and in the United States (US) approximately US$5–7 billion is spent on adults with pneumococcal disease [23, 24]. Costs are higher in adults ≥65 years of age when compared with ambulatory patients <65 years old [6, 25]. Based on data in this report, the majority of the financial burden of pneumococcal disease is for hospitalisation. More than A$50 million was spent on hospitalisation for pneumococcal pneumonia in 2011–2012, compared with approximately A$1.2 million that was spent on IPD cases in a similar period (Fig. 2b).

Strategies to reduce pneumococcal disease burden are primarily centred on vaccination. The 23-valent pneumococcal polysaccharide vaccine (PPSV23) is included in the Australian national immunisation programme for adults aged 65 years and over for protection against IPD, but protection wanes by 5 years after vaccination [26]. Although effective against IPD, a recent large-scale study of PPSV23 vaccination in more than 152,000 healthy adults clearly demonstrated no vaccine effect on pneumonia incidence [27]. These findings were confirmed in another study that showed vaccination was associated with a 42 % reduction in risk of IPD, but had no effect on pneumonia hospitalisation rates [28].

Although beneficial herd effects on all-cause pneumonia hospitalisation rates in older adults stemming from paediatric pneumococcal conjugate vaccine immunisation programmes have been observed in the US, these findings have not been replicated in Australia [29]. Hence, in some countries such as Australia, indirect effects from paediatric programs may foster improvements in disease burden for IPD in older adults, but may not affect the significant burden of pneumonia in these patients. These observations underscore the need for a mechanism to protect older adults from pneumococcal pneumonia that does not rely on herd effects. Results from a large European study of the 13-valent pneumococcal conjugate vaccine (PCV13) in adults aged ≥65 years indicate a vaccine effectiveness of 45.6 % in preventing the first episode of vaccine-serotype pneumococcal pneumonia and 75 % effectiveness against first episodes of vaccine-type IPD [30], which may have relevance for older adults in Australia. Indeed, a recent recommendation was made to include PCV13 on the national immunisation programme for the prevention of pneumococcal pneumonia and IPD in adults aged 65 years and over [31].

Given the presence of national immunisation programs for pneumococcal disease and influenza in older adults, comparison of the relative burdens of these illnesses may also be appropriate. Approximately 5 to 10 % of adults in Australia are also affected by respiratory infections caused by influenza, but these values are likely to be an underestimate of disease burden [32]. Despite an overall vaccine effectiveness of 50.9 % in elderly patients, influenza remains a substantial clinical and economic burden in Australia [32]. Between 2000 and 2006, more than 310,000 GP visits for influenza were recorded annually. The annual incidence of influenza hospitalisations in elderly adults ranged from 83.8 (95 % CI 55.7–111.9) per 100,000 population in individuals aged 65–74 years up to 378.2 (95 % CI 238.2–518.3) per 100,000 population in individuals >85 years of age [33]. Costs associated with influenza GP visits in adults aged 65–84 years were estimated at more than A$822,000 per year, with annual hospitalisation costs in those aged ≥65 years exceeding A$28.5 million. These costs are approximately half of the estimates for pneumococcal pneumonia in this study. Compared with pneumococcal pneumonia, the disease burden of influenza has been better studied and better recognised by healthcare professionals and the public. Influenza vaccination rates are also higher than those for pneumococcal vaccination [34], suggesting that a broader knowledge base to support public and medical professional awareness may contribute to higher vaccine uptake.

The current study adds much needed information surrounding the burden of pneumococcal pneumonia in elderly adults in Australia and may help in increasing awareness among healthcare professionals. The data presented provides essential information aimed at reducing the significant disease burden, such as the prevalence of pneumococcal pneumonia and the associated treatment costs.

A limitation of the present study stems from the majority of Australian pneumonia hospitalisations being reported as all-cause pneumonia; most cases are not categorised, and, therefore, the absolute proportion of pneumonia caused by S. pneumoniae remains somewhat uncertain. Less data on the aetiology of GP treated pneumonias are available than for hospitalised pneumonias, but there is a suggestion that pneumococcal pneumonia is more likely to be associated with increased severity and hence more likely to result in hospitalisation. For simplicity, the same calculations of the proportions of pneumococcal pneumonia for both pneumonia hospitalisation and pneumonia GP visits were undertaken, but this may result in an underestimate of pneumonia hospitalisation and an overestimate of pneumonia GP visits. In addition, diagnosis of hospitalised pneumonia is based on discharge coding and diagnosis of GP treated pneumonia is based on physician reporting. A recent paper suggested that a diagnosis of pneumonia was excluded for one-third of patients following a computer tomography (CT) scan [35].

Another limitation of the study is that the available data to inform this analysis were sourced from three different databases. Although there are overlaps with the time periods of data collection, it does mean that different populations were analysed. Despite these limitations, the current report addresses the paucity of data in the literature for the burden of pneumonia in older adults in Australia.

Continued epidemiologic study of pneumococcal pneumonia in adults aged 65 years and older may serve to increase clinical awareness of disease burden.


Pneumococcal disease in older adults in Australia represents a high clinical and economic healthcare burden. However, the burden of pneumonia remains less recognised than other diseases, such as influenza. The greatest burden of disease rests with pneumococcal pneumonia rather than IPD. Continued surveillance of pneumococcal pneumonia in adults living in Australia who are older than 65 years of age is essential.


  1. World Health Organization. Weekly epidemiological record. Available at: Accessed 20 June 2016.

  2. Morrill HJ, Caffrey AR, Noh E, Laplante KL. Epidemiology of pneumococcal disease in a national cohort of older adults. Infect Dis Ther. 2014;3:19–33. PMID:25134809,

    Article  PubMed  PubMed Central  Google Scholar 

  3. Ricketson LJ, Nettel-Aguirre A, Vanderkooi OG, Laupland KB, Kellner JD. Factors influencing early and late mortality in adults with invasive pneumococcal disease in Calgary, Canada: a prospective surveillance study. PLoS ONE. 2013;8, e71924. PMID:24115997,

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  4. Australian Bureau of Statistics. Population by Age and Sex. Regions of Australia, 2014. Available at: Accessed 20 June 2016.

  5. Said MA, Johnson HL, Nonyane BA, Deloria-Knoll M, O’Brien KL, Andreo F, et al. Estimating the burden of pneumococcal pneumonia among adults: a systematic review and meta-analysis of diagnostic techniques. PLoS ONE. 2013;8, e60273. PMID:23565216,

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Welte T, Torres A, Nathwani D. Clinical and economic burden of community-acquired pneumonia among adults in Europe. Thorax. 2012;67:71–9. PMID:20729232,

    Article  CAS  PubMed  Google Scholar 

  7. Musher DM, Rueda AM, Kaka AS, Mapara SM. The association between pneumococcal pneumonia and acute cardiac events. Clin Infect Dis. 2007;45:158–65. PMID:17578773,

    Article  PubMed  Google Scholar 

  8. Viasus D, Garcia-Vidal C, Manresa F, Dorca J, Gudiol F, Carratalà J. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community-acquired pneumonia. J Infect. 2013;66:27–33. PMID:22981899,

    Article  PubMed  Google Scholar 

  9. Griffin AT, Wiemken TL, Arnold FW. Risk factors for cardiovascular events in hospitalized patients with community-acquired pneumonia. Int J Infect Dis. 2013;17:e1125–9. PMID:24007923,

    Article  PubMed  Google Scholar 

  10. Charles PG, Whitby M, Fuller AJ, Stirling R, Wright AA, Korman TM, et al. Australian CAP study collaboration. The etiology of community-acquired pneumonia in Australia: why penicillin plus doxycycline or a macrolide is the most appropriate therapy. Clin Infect Dis. 2008;46:1513–21. PMID:18419484,

    Article  CAS  PubMed  Google Scholar 

  11. Li A, Newall AT, Britt H, Macintyre CR. The cost and disease burden of pneumonia in general practice in Australia. Vaccine. 2012;30:830–1. PMID:22154768,

    Article  CAS  PubMed  Google Scholar 

  12. Britt H, Miller GC, Henderson J, et al. General practice activity in Australia 2012–2013. Sydney: Sydney University Press; 2013.

    Google Scholar 

  13. Australian Bureau of Statistics. Australian Demographic Statistics, Estimated Resident Population by Single Year of Age, Australia. Available at: Accessed 20 June 2016.

  14. Australian Bureau of Statistics. Population Projections, by age and sex, Australia. Available at: Accessed 20 June 2016.

  15. Sinclair A, Xie X, Teltscher M, Dendukuri N. Systematic review and meta-analysis of a urine-based pneumococcal antigen test for diagnosis of community-acquired pneumonia caused by Streptococcus pneumoniae. J Clin Microbiol. 2013;51:2303–10. PMID:23678060,

  16. Horita N, Miyazawa N, Kojima R, Kimura N, Inoue M, Ishigatsubo Y, et al. Sensitivity and specificity of the Streptococcus pneumoniae urinary antigen test for unconcentrated urine from adult patients with pneumonia: a meta-analysis. Respirology. 2013;18:1177–83. PMID:23910720,

  17. Huijts SM, Pride MW, Vos JM, Jansen KU, Webber C, Gruber W, et al. Diagnostic accuracy of a serotype-specific antigen test in community-acquired pneumonia. Eur Respir J. 2013;42:1283–90. PMID:23397295,

    Article  PubMed  Google Scholar 

  18. Elberse K, van Mens S, Cremers AJ, Meijvis SC, Vlaminckx B, de Jonge MI, et al. Detection and serotyping of pneumococci in community acquired pneumonia patients without culture using blood and urine samples. BMC Infect Dis. 2015;15:56. PMID:25885896,

    Article  PubMed  PubMed Central  Google Scholar 

  19. Australian National Hospital Cost Data Collection for public hospitals. AR-DRG version 5.2, round 13 (2008–2009). Available at:$File/HeaderR13CWNatEst.pdf. Accessed 20 June 2016.

  20. Barry C, Krause VL, Cook HM, Menzies RI. Invasive pneumococcal disease in Australia 2007 and 2008. Commun Dis Intell Q Rep. 2012;36:E151–65. PMID:23186214.

    PubMed  Google Scholar 

  21. Roche P, Krause V, Cook H, Bartlett M, Coleman D, Davis C, et al. Enhanced Invasive Pneumococcal Diseases Surveillance Working Group. Invasive pneumococcal disease in Australia, 2005. Commun Dis Intell Q Rep. 2007;31:86–100. PMID:17503648.

  22. European Respiratory Society. The Economic Burden of Lung Disease. European Lung White Book Lausanne, Switzerland: European Respiratory Society, 2011:16–27. Available at: Accessed 20 June 2016.

  23. Weycker D, Strutton D, Edelsberg J, Sato R, Jackson LA. Clinical and economic burden of pneumococcal disease in older US adults. Vaccine. 2010;28:4955–60. PMID:20576535,

    Article  PubMed  Google Scholar 

  24. Thomas CP, Ryan M, Chapman JD, Stason WB, Tompkins CP, Suaya JA, et al. Incidence and cost of pneumonia in Medicare beneficiaries. Chest. 2012;142:973–81. PMID:22406959,

    Article  PubMed  Google Scholar 

  25. Bartolomé M, Almirall J, Morera J, Pera G, Ortún V, Bassa J, et al. Maresme Community-Acquired Pneumonia Study Group (GEMPAC). A population-based study of the costs of care for community-acquired pneumonia. Eur Respir J. 2004;23:610–6. PMID:15083763,

  26. Andrews NJ, Waight PA, George RC, Slack MP, Miller E. Impact and effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive pneumococcal disease in the elderly in England and Wales. Vaccine. 2012;30:6802–8. PMID:23000122,

    Article  PubMed  Google Scholar 

  27. Russell KL, Baker CI, Hansen C, Poland GA, Ryan MA, Merrill MM, et al. Lack of effectiveness of the 23-valent polysaccharide pneumococcal vaccine in reducing all-cause pneumonias among healthy young military recruits: a randomized, double-blind, placebo-controlled trial. Vaccine. 2015;33:1182–7. PMID:25579777,

    Article  CAS  PubMed  Google Scholar 

  28. Leventer-Roberts M, Feldman BS, Brufman I, Cohen-Stavi CJ, Hoshen M, Balicer RD. Effectiveness of 23-valent pneumococcal polysaccharide vaccine against invasive disease and hospital-treated pneumonia among people aged ≥65 years: a retrospective case-control study. Clin Infect Dis. 2015;60:1472–80. PMID:25669354.

  29. Menzies RI, Jardine A, McIntyre PB. Pneumonia in elderly Australians: reduction in presumptive pneumococcal hospitalizations but no change in all-cause pneumonia hospitalizations following 7-valent pneumococcal conjugate vaccination. Clin Infect Dis. 2015;61:927–33. PMID:26066319,

  30. Bonten MJ, Huijts SM, Bolkenbaas M, Webber C, Patterson S, Gault S, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in adults. N Engl J Med. 2015;372:1114–25. PMID:25785969,

    Article  CAS  PubMed  Google Scholar 

  31. Australian Government Department of Health. Pneumococcal conjugate vaccine (13-valent); 0.5 mL injection; Prevenar 13®. Available at: Accessed 20 June 2016.

  32. Cheng AC, Dwyer DE, Holmes M, Irving LB, Brown SG, Waterer GW, et al. Influenza epidemiology, vaccine coverage and vaccine effectiveness in sentinel Australian hospitals in 2013: the Influenza Complications Alert Network. Commun Dis Intell Q Rep. 2014;38:E143–9. PMID:25222208.

  33. Newall AT, Scuffham PA. Influenza-related disease: the cost to the Australian healthcare system. Vaccine. 2008;26:6818–23. PMID:18940222,

    Article  PubMed  Google Scholar 

  34. Song JY, Lee JS, Wie SH, Kim HY, Lee J, Seo YB, et al. Prospective cohort study on the effectiveness of influenza and pneumococcal vaccines in preventing pneumonia development and hospitalization. Clin Vaccine Immunol. 2015;22:229–34. PMID:25540271,

    Article  CAS  PubMed  Google Scholar 

  35. Claessens YE, Debray MP, Tubach F, Brun AL, Rammaert B, Hausfater P, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015;192:974–82. PMID:26168322, Available at:

Download references


Information in this report has been drawn from data from the Australian Institute of Health and Welfare (AIHW), the National Notifiable Diseases Surveillance System Invasive Pneumococcal Disease Public Data Set, the Australian Bureau of Statistics (ABS), and the Bettering Evaluation and Care of Health (BEACH) Program, a project of the Family Medicine Research Centre, the University of Sydney, Australia. Writing support was provided by Jill E. Kolesar, PhD, of Complete Healthcare Communications, LLC, and was funded by Pfizer Inc.


This study was funded by Pfizer. The sponsor was involved in study design, data collection, analysis, and interpretation, writing of the manuscript, and the decision to submit the manuscript.

Authors’ contribution

Both authors meet ICMJE criteria for authorship. and both authors conceived, generated and designed the study, collected and analysed data, and provided critical review of the manuscript for important intellectual content. Both authors read and approved the final manuscript.

Competing interest

Kylie Earle and Scott Williams are employees of Pfizer Australia and may hold shares in Pfizer.

Author information

Authors and Affiliations


Corresponding author

Correspondence to Kylie Earle.

Rights and permissions

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (, which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver ( applies to the data made available in this article, unless otherwise stated.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Earle, K., Williams, S. Burden of pneumococcal disease in adults aged 65 years and older: an Australian perspective. pneumonia 8, 9 (2016).

Download citation

  • Received:

  • Accepted:

  • Published:

  • DOI: